Effect of different treatments and alcohol addiction on gut microbiota in minimal hepatic encephalopathy patients

Zuo,Zan; Fan,Hong; Tang,Xiao‑Dan; Chen,Yan‑Min; Xun,Lin‑Ting; Li,Yan; Song,Zheng‑Ji; Zhai,Hui‑Qiong

doi:10.3892/etm.2017.5141

Effect of different treatments and alcohol addiction on gut microbiota in minimal hepatic encephalopathy patients

Authors:
- Zan Zuo
- Hong Fan
- Xiao‑Dan Tang
- Yan‑Min Chen
- Lin‑Ting Xun
- Yan Li
- Zheng‑Ji Song
- Hui‑Qiong Zhai
View Affiliations

Affiliations: College of Environmental Science and Engineering, Kunming University of Science and Technology, Kunming, Yunnan 650500, P.R. China, Department of Gastroenterology, Affiliated Hospital of Kunming University of Science and Technology, The First People's Hospital of Yunnan, Kunming, Yunnan 650532, P.R. China, Department of Gastroenterology, Yanan Hospital of Kunming, Kunming, Yunnan 650032, P.R. China
Published online on: September 19, 2017 https://doi.org/10.3892/etm.2017.5141
Pages: 4887-4895
Copyright: © Zuo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Minimal hepatic encephalopathy (MHE) is caused by dysbiosis of gut microbiota, particularly the ammonia‑producing bacteria. Given the efficacy of certain treatments on MHE and the connection between alcoholism and MHE, a thorough understanding of how these strategies affect the gut microbiota in patients (alcoholic or non‑alcoholic) will facilitate the assessment of their efficacy in the reshaping of gut microbiota. In the present study, a metagenomics approach was adopted to reveal alterations in gut microbiota of 14 MHE patients following treatment with rifaximin alone or rifaximin plus probiotics. Patients were grouped into the alcoholic and non‑alcoholic groups to examine differences in terms of their response to treatment. Treatment reduced the overall microbiota diversity and decreased the abundance of certain ammonia‑producing bacteria, such as Clostridium, with the treatment of rifaximin plus probiotics presenting a more apparent effect. Non‑alcoholic MHE patients responded better to the treatment, as they presented greater reduction in microbiota diversity and a more consistent decline in certain ammonia‑producing bacteria genera (such as Clostridium and Streptococcus) belonging to the Firmicutes phylum. In conclusion, treatment with rifaximin alone and rifaximin plus probiotics exhibited a different effect in different MHE patients, decreasing the overall gut microbiota diversity to various extents and reshaping microbiota in different ways. Furthermore, non‑alcoholic MHE patients responded better to treatment in microbiota alterations.

View Figures

View References

1	Dbouk N and McGuire BM: Hepatic encephalopathy: A review of its pathophysiology and treatment. Curr Treat Options Gastroenterol. 9:464–474. 2006. View Article : Google Scholar : PubMed/NCBI
2	Kato A, Tanaka H, Kawaguchi T, Kanazawa H, Iwasa M, Sakaida I, Moriwaki H, Murawaki Y, Suzuki K and Okita K: Nutritional management contributes to improvement in minimal hepatic encephalopathy and quality of life in patients with liver cirrhosis: A preliminary, prospective, open-label study. Hepatol Res. 43:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
3	Amodio P, Montagnese S, Gatta A and Morgan MY: Characteristics of minimal hepatic encephalopathy. Metab Brain Dis. 19:253–267. 2004. View Article : Google Scholar : PubMed/NCBI
4	Bernardini P and Fischer JE: Amino acid imbalance and hepatic encephalopathy. Annu Rev Nutr. 2:419–454. 1982. View Article : Google Scholar : PubMed/NCBI
5	Norman K and Pirlich M: Gastrointestinal tract in liver disease: Which organ is sick? Curr Opin Clin Nutr Metab Care. 11:613–619. 2008. View Article : Google Scholar : PubMed/NCBI
6	Prakash R and Mullen KD: Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 7:515–525. 2010. View Article : Google Scholar : PubMed/NCBI
7	Kawaguchi T, Taniguchi E and Sata M: Effects of oral branched-chain amino acids on hepatic encephalopathy and outcome in patients with liver cirrhosis. Nutr Clin Pract. 28:580–588. 2013. View Article : Google Scholar : PubMed/NCBI
8	Riordan SM and Williams R: Gut flora and hepatic encephalopathy in patients with cirrhosis. N Engl J Med. 362:1140–1142. 2010. View Article : Google Scholar : PubMed/NCBI
9	Kawaguchi T, Taniguchi E and Sata M: Motor vehicle accidents: How should cirrhotic patients be managed? World J Gastroenterol. 18:2597–2599. 2012. View Article : Google Scholar : PubMed/NCBI
10	Kawaguchi T, Suetsugu T, Ogata S, Imanaga M, Ishii K, Esaki N, Sugimoto M, Otsuyama J, Nagamatsu A, Taniguchi E, et al: An association between dietary habits and traffic accidents in patients with chronic liver disease: A data-mining analysis. Biomed Rep. 4:615–622. 2016. View Article : Google Scholar : PubMed/NCBI
11	Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, et al: Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 362:1071–1081. 2010. View Article : Google Scholar : PubMed/NCBI
12	Zhan T and Stremmel W: The diagnosis and treatment of minimal hepatic encephalopathy. Dtsch Arztebl Int. 109:180–187. 2012.PubMed/NCBI
13	Kumar MS, Kaur G and Sandhu AK: Genomic DNA isolation from fungi, algae, plant, bacteria and human blood using CTAB. Int J Sci Res. 3:617–618. 2014.
14	Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, et al: A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 464:59–65. 2010. View Article : Google Scholar : PubMed/NCBI
15	Kindt R and Coe R: Tree diversity analysis: A manual and software for common statistical methods for ecological and biodiversity studies. World Agroforestry Centre. 2005.
16	Khoruts A and Sadowsky MJ: Therapeutic transplantation of the distal gut microbiota. Mucosal Immunol. 4:4–7. 2011. View Article : Google Scholar : PubMed/NCBI
17	Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC and Siuzdak G: Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci USA. 106:3698–3703. 2009. View Article : Google Scholar : PubMed/NCBI
18	MacDonald TT, Monteleone I, Fantini MC and Monteleone G: Regulation of homeostasis and inflammation in the intestine. Gastroenterology. 140:1768–1775. 2011. View Article : Google Scholar : PubMed/NCBI
19	Cho I and Blaser MJ: The human microbiome: At the interface of health and disease. Nat Rev Genet. 13:260–270. 2012.PubMed/NCBI
20	Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White MB, Monteith P, Noble NA, Sikaroodi M and Gillevet PM: Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol. 303:G675–G685. 2012. View Article : Google Scholar : PubMed/NCBI
21	Bajaj JS, Ridlon JM, Hylemon PB, Thacker LR, Heuman DM, Smith S, Sikaroodi M and Gillevet PM: Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol. 302:G168–G175. 2012. View Article : Google Scholar : PubMed/NCBI
22	Bajaj JS, Heuman DM, Sanyal AJ, Hylemon PB, Sterling RK, Stravitz RT, Fuchs M, Ridlon JM, Daita K, Monteith P, et al: Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One. 8:e600422013. View Article : Google Scholar : PubMed/NCBI
23	Rijkers GT, de Vos WM, Brummer RJ, Morelli L, Corthier G and Marteau P: Health benefits and health claims of probiotics: Bridging science and marketing. Br J Nutr. 106:1291–1296. 2011. View Article : Google Scholar : PubMed/NCBI
24	Kuang YS, Li SH, Guo Y, Lu JH, He JR, Luo BJ, Jiang FJ, Shen H, Papasian CJ, Pang H, et al: Composition of gut microbiota in infants in China and global comparison. Sci Rep. 6:366662016. View Article : Google Scholar : PubMed/NCBI
25	Jain L, Sharma BC, Srivastava S, Puri SK, Sharma P and Sarin S: Serum endotoxin, inflammatory mediators, and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy. J Gastroenterol Hepatol. 28:1187–1193. 2013. View Article : Google Scholar : PubMed/NCBI
26	Zhang Z, Zhai H, Geng J, Yu R, Ren H, Fan H and Shi P: Large-scale survey of gut microbiota associated with MHE Via 16S rRNA-based pyrosequencing. Am J Gastroenterol. 108:1601–1611. 2013. View Article : Google Scholar : PubMed/NCBI
27	Oakley CL and Warrack GH: The alpha, beta and gamma antigens of Clostridium histolyticum (Weinberg & Séguin, 1916). J Gen Microbiol. 4:365–373. 1950. View Article : Google Scholar : PubMed/NCBI